Osteoporosis International

, Volume 11, Issue 1, pp 83–91

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis


  • J.-Y. Reginster
    • Centre Universitaire d’Investigation du Me´tabolisme Osseux et du Cartilage Articulaire, University of Lie`ge, Belgium
  • H. W. Minne
    • Clinic for Metabolic Bone Disease, Bad Pyrmont, Germany
  • O. H. Sorensen
    • Copenhagen Municipal Hospital, Copenhagen, Denmark
  • M. Hooper
    • University of Sydney and Concord Repatriation General Hospital, Sydney, Australia
  • C. Roux
    • Cochin Hospital, Rene´ Descartes University, Paris, France
  • M. L. Brandi
    • University of Florence, Florence, Italy
  • B. Lund
    • Copenhagen, Denmark
  • D. Ethgen
    • Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA;
  • S. Pack
    • Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA;
  • I. Roumagnac
    • Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, USA;
  • R. Eastell
    • University of Sheffield, Sheffield, UK
  • on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
Original Article

DOI: 10.1007/s001980050010

Cite this article as:
Reginster, J., Minne, H., Sorensen, O. et al. Osteoporos Int (2000) 11: 83. doi:10.1007/s001980050010


The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n= 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p= 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p= 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease.

Key words:Bisphosphonates – Bone mineral density – Osteoporosis – Postmenopausal women – Risedronate – Vertebral fracture

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2000